Lyra Therapeutics, Inc.

LYRA

US55234L1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.291 ^USD	-0.34%		+6.99%	-94.45%

Jul. 01	Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Comp Value Index	CI
Jul. 01	Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Completeness Index	CI

Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 2500 Growth Index

July 30, 2024

Latest news about Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Completeness Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000 Value Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 2000 Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000E Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 2500 Value Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000 Growth Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 2000 Value Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000E Growth Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 2000 Growth Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 2000 Dynamic Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 2500 Growth Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 2500 Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000 Index	Jun. 30	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000E Value Index	Jun. 30	CI
Lyra Therapeutics Reduces Workforce to Extend Cash Runway	May. 21	MT
Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024	May. 21	CI
Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital	May. 21	CI
Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50	May. 07	MT
HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy	May. 07	MT
Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell	May. 06	MT
Lyra Therapeutics Lead Drug Candidate Fails in Phase 3 Study	May. 06	DJ
Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis	May. 06	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lyra Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.291 USD

Average target price

4.5 USD

Spread / Average Target

+1,446.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LYRA THERAPEUTICS, INC.	-94.45%	17.74M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research